A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma

Cancer

Volumn 85, Issue 9, 1999, Pages 1979-1984

  Agarwala, Sanjiv S ^a   Ferri, William ^a   Gooding, William ^a   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Hormonal therapy; Melanoma; Metastasis; Tamoxifen

Indexed keywords

CARBOPLATIN; DACARBAZINE; TAMOXIFEN;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DACARBAZINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0033135342     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990501)85:9<1979::AID-CNCR15>3.0.CO;2-G     Document Type: Article

References (13)

1. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in malignant melanoma. Cancer Treat Rep 1984;68:1403-5.
2. McClay EF, Mastrangelo MJ, Bellet RE, Berd D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987;71:465-9.
3. McClay EF, Mastrangelo MJ, Bellet RE, et al. An effective chemo/hormonal therapy regimen for the treatment of disseminated malignant melanoma. Proc Am Soc Clin Oncol 1989;8:282.
4. Lattanzi SC, Tosteson T, Chertoff J, Maurer LH, O'Donnell J, LeMarbre PJ, et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995;5:365-9.
5. Nesbit RA, Woods RL, Tattersall MH, Fox RM, Forbes JF, MacKay IR, et al. Tamoxifen in malignant melanoma. N Engl J Med 1979;301:1241-2.
6. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl JMed 1992;327:516-23.
7. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14: 2083-90.
8. Van Echo DA, Egorin MJ, Aisner J, The pharmacology of carboplatin. Semin Oncol 1989;16:1-6.
9. Simon R. Designs for efficient clinical trials. Oncology 1989; 3:43-53.
10. McClay EF, Albright KD, Jones JA, Eastman A, Christen R, Howell SB. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 1992;52:6790-6.
11. McClay EF, Albright KD, Jones JA, Christen RD, Howell SB. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 1993;53:1571-6.
12. Luger SM, Kirkwood JM, Ernstoff MS, Vlock DR. High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst 1990;82:1934-7.
13. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study (E3690). J Clin Oncol 1998; 16:1743-51.